SCHEMBL30989923

SCHEMBL30989923

CN(Cc1cccc(F)c1)C(=O)c1cc(Cl)cnc1OC(F)F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ SCD5 Q86SK9 1/20 0.44
▸ RIPK1 Q13546 1/20 0.42
▸ CLK1 P49759 1/20 0.42
▸ CLK2 P49760 1/20 0.42
▸ DYRK1A Q13627 1/20 0.42
▸ CLK4 Q9HAZ1 1/20 0.42
▸ DYRK1B Q9Y463 1/20 0.42
▸ PPARG P37231 2/20 0.40
▸ PPARA Q07869 1/20 0.40
▸ HSP90AA1 P07900 2/20 0.40
▸ PTGER4 P35408 1/20 0.39
▸ PTGER2 P43116 1/20 0.39
▸ HSD17B1 P14061 1/20 0.39
▸ HSD17B2 P37059 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ THRA P10827 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30989806 0.92 GRM5 (0.45) ALDH1A1HPGDMEN1KMT2ARIPK1
SCHEMBL30989812 0.91 MEP1B (0.44) ALDH1A1HPGDMEN1KMT2ARIPK1
SCHEMBL30989972 0.91 ALDH1A1 (0.49) ALDH1A1HPGDMEN1KMT2ASCD5
SCHEMBL30989857 0.90 HSP90AA1 (0.52) KMT2AHSP90AA1HSD17B1HSD17B2HTT
SCHEMBL30989808 0.89 HTT (0.39) ALDH1A1HPGDCLK1CLK2DYRK1A
SCHEMBL30989909 0.89 CLK1 (0.48) ALDH1A1HPGDMEN1KMT2ASCD5
SCHEMBL30989922 0.88 POLB (0.49) ALDH1A1HPGDMEN1KMT2ARIPK1
SCHEMBL30989793 0.88 HTT (0.38) ALDH1A1HPGDMEN1KMT2ACLK1
SCHEMBL30989807 0.87 TACR1 (0.47) HPGDPTGER4
SCHEMBL30989861 0.86 RIPK1 (0.49) HPGDRIPK1PTGER4HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612131-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 — — EP disclosed
WO-2024095003-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2024-05-10 — — WO disclosed
Send feedback